AGILeBiotics is focused and dedicated to develop novel antibacterials to treat patients infected by life-threatening hospital-acquired multidrug-resistant infections.
AGILeBiotics is committed to the fight against bacterial resistance with the aim to bring innovative therapeutic solutions to patients infected by multidrug-resistant (MDR) infections.
According to the World Health Organization (WHO) and the Infectious Disease Society of America (IDSA) the world is entering the post-antibiotic era, with no therapy option left for patients infected by MDR pathogens. Without acceleration of antibiotic development, death rate will increase 10-fold by 2050, reaching 250.000 deaths in Europe and 10 million deaths worldwide. In addition, the U.S. Center for Disease Control and Prevention (CDC) estimates that antibiotic resistance is responsible for more than two million infections and 23,000 deaths each year in the United States, at a direct cost of $20 billion and additional productivity losses of $35 billion. By 2050, antimicrobial resistance is projected to result in global GDP loss of more than >$100 trillion.
The society is running out of treatment options especially against MDR infections caused by bacteria belonging to the alarming ESKAPE panel: Enterococcus faecium (Gram+), Staphylococcus aureus (Gram+), Klebsiella pneunomiae (Gram-), Acinetobacter baumannii (Gram-), Pseudomonas aeruginosa (Gram-), Enterobacteriaceae spp. (Gram-). Patients in intensive care suffering from ventilator-associated pneumonia (VAP), urinary tract infection (UTI) or sepisi are treated with toxic last-resort antibiotics or left with not effective therapy options.
Especially infections caused by Carbapenem-resistant-Enterobacteriaceae (CRE), MDR A. baumanii and P. aeruginosa represent the most urgent threat to society as emphasized by the WHO. Examples for those infections are intra-abdominal infections, UTIs, VAP, blood stream infections (BSI) and sepsis. The percentage of carbapenem-resistant bacterial isolates of Klebsiella pneumonia is rising world-wide, reaching approx. 60% in Greece. Due to the fact, that we lack treatment options for CRE infections, the mortality rate for BSIs is as high as 50% according to CDC. Moreover, it is projected that by 2025 CRE infections will increase 3-fold reaching more than 400.000 infections in US and Europe. This alarming trend shows the urgent need for innovative medicine especially for patients in intensive care units.
Unfortunately, antibiotic development still takes 10 to 15 years, and most new antibiotic candidates fail in clinical trials due to toxicity and safety reasons. Reviving an existing class of antibiotics and working on natural product-based antibiotic candidates are still the most successful strategies to accelerate antibiotic development and increase the chance for approval of novel antibiotics by regulatory bodies. This approach increases the success rate during clinical trials by 300-fold.
At AGILeBiotics we are focusing on the identification and development of novel antibiotics, which are based on natural products. Our proprietary technologies simplify not only the structural modification of complex natural products but give also access to the ‘next generation’ antibiotics. With our modification strategies we accelerate our in-house antibiotics development against the most life-threatening MDR bacteria, i.e. CRE infections.
Our long-term goal is to out-license an antibiotic candidate after clinical Phase IIa to a large pharmaceutical company. We aim to advance our antibiotic candidates into clinical development in 2020.